Drug Profile
Research programme: oncology and immunotherapy therapies - Bristol-Myers Squibb/Tshinghua University
Latest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Tsinghua University
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer
Most Recent Events
- 30 Dec 2022 Discontinued for Autoimmune disorders in China (unspecified route)
- 30 Dec 2022 Discontinued for Cancer in China (unspecified route)
- 28 Jul 2020 No recent reports of development identified for research development in Autoimmune-disorders in China